Leading BioSciences Announces Top Line Phase 2 Data Demonstrating LB1148 Achieves Primary Endpoint with Statistically Significant Improvement in Bowel Function Following Cardiovascular Surgery

    NEXT STORY
    Global Facial/Surgical Mask Market Observing a CAGR of 20.0% during 2020–2025: VynZ Research
    PREV STORY
    SORRENTO COLLABORATES WITH MABPHARM ON DEVELOPMENT AND COMMERCIALIZATION OF ACE-MAB™ TO POTENTIALLY TREAT COVID-19
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Saniona publishes its interim report for the second quarter 2020

    author_avatar
    NASDAQ Market News

    Phase III data show Roche’s Port Delivery System with ranibizumab enabled over 98% of patients to go six months between treatments for neovascular age-related macular degeneration

    author_avatar
    NASDAQ Market News

    Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors

    author_avatar
    NASDAQ Market News